Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934382 · ClinicalTrials.gov registry record · Phase 1
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
A Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06934382: Recruiting Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma, sponsored by Stephan Grupp MD PhD.
NCT06934382 is a Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06934382, a Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Primary Outcome
The Maximum Tolerated Dose will be determined by measuring the incidence of dose limiting toxicities following administration of the product.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2031-05-30 |
| Phase | Phase 1 |
What NCT06934382 shows while recruiting
NCT06934382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 1 condition, with T-Cell Acute Lymphoblastic Leukemia/Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic anti-CD7 CAR-T cells (BEAM-201) is the first listed.
NCT06934382 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06934382 about?
NCT06934382 is a clinical study titled "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma". This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
What is the current status of trial NCT06934382?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-04-29. Estimated completion is 2031-05-30.
What conditions does trial NCT06934382 study?
This clinical trial studies the following conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma.
What interventions are being tested in trial NCT06934382?
The interventions under investigation include: Allogeneic anti-CD7 CAR-T cells (BEAM-201) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06934382?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934382 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06934382's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI